These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 29909914)

  • 21. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
    Salaroli A; Spilleboudt C; Bron D; Lewalle P
    Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
    Munshi PN; Ujjani C
    Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
    Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report.
    Zhong N; Ma Q; Gong S; Shi Y; Zhao L; Wang D; Zhou H; Liu N; Ye Y; Wang J; Liu L; Guo Z
    Int Immunopharmacol; 2024 Jun; 134():112174. PubMed ID: 38703571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
    Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
    N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD19-directed CAR T-cell therapy in B-cell NHL.
    Kersten MJ; Spanjaart AM; Thieblemont C
    Curr Opin Oncol; 2020 Sep; 32(5):408-417. PubMed ID: 32740094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
    Jin Z; Xiang R; Qing K; Li D; Liu Z; Li X; Zhu H; Zhang Y; Wang L; Xue K; Liu H; Xu Z; Wang Y; Li J
    Cell Oncol (Dordr); 2023 Aug; 46(4):1143-1157. PubMed ID: 37219767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
    Watkins MP; Bartlett NL
    Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study.
    Yuen C; Rezania K; Kelly T; Bishop MR
    Immunotherapy; 2021 Oct; 13(15):1261-1269. PubMed ID: 34558978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
    Othman T; Baird JH; Pak S; Mei M; Herrera AF; Mansour J; Shouse G; Sahebi F; Spielberger R; Cai JL; Farol L; Godfrey J; Kallam A; Phillips T; Popplewell L; Siddiqi T; Forman S; Budde LE
    Br J Haematol; 2024 Jul; 205(1):368-372. PubMed ID: 38797530
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
    Zhang Y; Wang Y; Liu Y; Tong C; Wang C; Guo Y; Ti D; Yang Q; Qiao S; Wu Z; Han W
    Leukemia; 2022 Jan; 36(1):189-196. PubMed ID: 34272481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells.
    Nagler A; Perriello VM; Falini L; Falini B
    Br J Haematol; 2023 May; 201(3):396-410. PubMed ID: 36916189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
    Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.
    Ghobadi A
    Curr Res Transl Med; 2018 May; 66(2):43-49. PubMed ID: 29655961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.
    Martín-Martín L; Gutiérrez-Herrero S; Herrero-García M; Martín García-Sancho A; Yeguas A; Martín-López AÁ; López-Corral L; Pérez-López E; García-Blázquez M; Sánchez-Guijo F; Vidriales MB; Gaipa G; ; ; Orfao A
    Blood Cancer J; 2024 May; 14(1):83. PubMed ID: 38760376
    [No Abstract]   [Full Text] [Related]  

  • 38. CAR T-cell therapy in refractory large B-cell lymphoma.
    Stirrups R
    Lancet Oncol; 2018 Jan; 19(1):e19. PubMed ID: 29249304
    [No Abstract]   [Full Text] [Related]  

  • 39. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
    Mihăilă RG
    Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
    Morschhauser F; Dahiya S; Palomba ML; Martin Garcia-Sancho A; Reguera Ortega JL; Kuruvilla J; Jäger U; Cartron G; Izutsu K; Dreyling M; Kahl B; Ghesquieres H; Ardeshna K; Goto H; Barbui AM; Abramson JS; Borchmann P; Fleury I; Mielke S; Skarbnik A; de Vos S; Kamdar M; Karmali R; Viardot A; Farazi T; Fasan O; Lymp J; Vedal M; Nishii R; Avilion A; Papuga J; Kumar J; Nastoupil LJ
    Nat Med; 2024 Aug; 30(8):2199-2207. PubMed ID: 38830991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.